Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-08-09
2005-08-09
Davis, Brian J. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S634000, C544S163000, C564S238000, C564S239000
Reexamination Certificate
active
06927218
ABSTRACT:
Compounds, compositions and methods treating arthritic disorders such as osteoarthritis or rheumatoid arthritis, and for treating other diseases associated with altered mitochondrial function, such as cancer, psoriasis, stroke, Alzheimer's Disease and diabetes. The compounds of this invention have the following structure (I):including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1-5are as defined herein. The methods of this invention are directed to administering to a warm-blooded animal in need thereof an effective amount of a compound of structure (I), typically in the form of a pharmaceutical composition.
REFERENCES:
patent: 4265905 (1981-05-01), Shen et al.
patent: 4654342 (1987-03-01), Slater
patent: WO 01/72728 (2001-10-01), None
Database CAPLUS on STN, Acc. No. 1979:133326, Warner et al., J. Med. Chem. (1979), 22(4), p. 359-66 (abstract).
Database CAPLUS on STN, Acc. No. 1981:46923, Husain et al., Indian Drugs, (1980), 17(10), p. 315-17 (abstract).
Database CAPLUS on STN, Acc. No. 1986:34098, WO 8503076 (abstract).
Chen et al., “Regio- and stereoselective ring opening of epoxide with cyanoguanide dianions, a facile synthesis of the KATPopener BMS-180448,”Tetrahedron: Asymmetry 9:1337-1340, 1998.
Cunningham et al., “13C and15N NMR Study of Electron Distribution in N-Aryl-N1-cyanoguanidines,”Magnetic Resonance in Chemistry 34(3):221-226, 1996.
Cunningham et al., “Acidity and N-methylation of N-aryl-N1-cyanoguanidines,”J. Chem. Soc., Perkin Trans. 2(4):693-697, 1999.
Jones et al., “Lewis Acid Assisted Cyclization of Arylcyanoguanidines to 2,4-Diaminoquinazolines,”J. Heterocycl. Chem. 31(6):1681-1683, 1994.
Kreutzberger et al., “2-Guanidino-4(3H)-chinazolinone mit chemotherapeutischen Eigenschaften,”Pharmazie 48(1):17-20, 1993.
Kuyper et al., “High-Affinity Inhibitors of Dihydrofolate Reductase: Antimicrobial and Anticancer Activities of 7,8-Dialkyl-1, 3-diaminopyrrolo[3,2-f]quinazolines with Small Molecular Size,”J. Med Chem. 39:892-903, 1996.
Miller et al., “The Synthesis of Aminoiminoethanenitriles,” 5-Aminotetrazoles, N-Cyanoguanidines and N-Hydorxyguanidines from Aminoiminomethanesulfonic acids,Synthetic Communications 20(2):217-226, 1990.
Stevens et al., “Potent and Selective Indolomorphinan Antagonists of the Kappa-Opioid Receptor,”J. Med. Chem. 43:2759-2769, 2000.
Tilly et al., “The Synthesis of 3,5-Diamino-1,2,4-oxadiazoles,”Helvetica Chimica Acta 63(4):841-859, 1980.
Database CAPLUS on STN, Acc. No. 1979:133326, Warner et al., J. Med. Chem. (1979), 22(4), p. 359-66 (abstract).
Database CAPLUS on STN, Acc. No. 1981:46923, Husain et al., Indian Drugs, (1980), 17(10), p. 315-17 (abstract).
Ghosh Soumitra S.
Szabo Tomas R.
Davis Brian J.
Migenix Corp.
Seed IP Law Group PLLC
LandOfFree
Aryl N-cyanoguanidines and methods related thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl N-cyanoguanidines and methods related thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl N-cyanoguanidines and methods related thereto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3442849